In the present study, we hypothesized that the lncRNA CHRF/miR-489/ Myd88 axis served as novel biomarkers for the treatment and diagnosis of patients with NSCLC and we endeavored to explore the role that IL-1β played in this process. This evidence concerns the gene MYD88 and non-small cell lung carcinoma.